Abstract
A 24-year-old man with disseminated herpes zoster, which occurred 9 months after bone marrow transplantation for chronic myeloid leukemia, developed encephalopathy and immobilizing myoclonus after 7 days of vidarabine treatment (10 mg/kg of body weight per day). Only mild hepatic dysfunction was a risk factor for a toxic reaction. After the vidarabine therapy was stopped, the symptoms worsened until treatment with hydration, large doses of chlordiazepoxide, and protective care gave symptomatic relief.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Collignon P. J., Sorrell T. C. Neurological toxicity associated with vidarabine (adenine arabinoside) therapy. Aust N Z J Med. 1983 Dec;13(6):627–629. doi: 10.1111/j.1445-5994.1983.tb02618.x. [DOI] [PubMed] [Google Scholar]
- Cullis P. A., Cushing R. Vidarabine encephalopathy. J Neurol Neurosurg Psychiatry. 1984 Dec;47(12):1351–1354. doi: 10.1136/jnnp.47.12.1351. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lauter C. B., Bailey E. J., Lerner A. M. Microbiologic assays and neurological toxicity during use of adenine arabinoside in humans. J Infect Dis. 1976 Jul;134(1):75–79. doi: 10.1093/infdis/134.1.75. [DOI] [PubMed] [Google Scholar]
- Marker S. C., Howard R. J., Groth K. E., Mastri A. R., Simmons R. L., Balfour H. H., Jr A trial of vidarabine for cytomegalovirus infection in renal transplant patients. Arch Intern Med. 1980 Nov;140(11):1441–1444. [PubMed] [Google Scholar]
- Meyers J. D., McGuffin R. W., Bryson Y. J., Cantell K., Thomas E. D. Treatment of cytomegalovirus pneumonia after marrow transplant with combined vidarabine and human leukocyte interferon. J Infect Dis. 1982 Jul;146(1):80–84. doi: 10.1093/infdis/146.1.80. [DOI] [PubMed] [Google Scholar]
- Nadel A. M. Vidarabine therapy for herpes simplex encephalitis. The development of an unusual tremor during treatment. Arch Neurol. 1981 Jun;38(6):384–385. doi: 10.1001/archneur.1981.00510060086019. [DOI] [PubMed] [Google Scholar]
- Ramos E., Timmons R. F., Schimpff S. C. Inappropriate antidiuretic hormone following adenine arabinoside administration. Antimicrob Agents Chemother. 1979 Jan;15(1):142–144. doi: 10.1128/aac.15.1.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sacks S. L., Scullard G. H., Pollard R. B., Gregory P. B., Robinson W. S., Merigan T. C. Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination. Antimicrob Agents Chemother. 1982 Jan;21(1):93–100. doi: 10.1128/aac.21.1.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Van Etta L., Brown J., Mastri A., Wilson T. Fatal vidarabine toxicity in a patient with normal renal function. JAMA. 1981 Oct 9;246(15):1703–1705. doi: 10.1001/jama.246.15.1703. [DOI] [PubMed] [Google Scholar]
- Whitley R. J., Ch'ien L. T., Dolin R., Galasso G. J., Alford C. A., Jr Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study. N Engl J Med. 1976 May 27;294(22):1193–1199. doi: 10.1056/NEJM197605272942201. [DOI] [PubMed] [Google Scholar]
- Whitley R. J., Soong S. J., Dolin R., Betts R., Linnemann C., Jr, Alford C. A., Jr Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. N Engl J Med. 1982 Oct 14;307(16):971–975. doi: 10.1056/NEJM198210143071602. [DOI] [PubMed] [Google Scholar]
- Whitley R. J., Soong S. J., Hirsch M. S., Karchmer A. W., Dolin R., Galasso G., Dunnick J. K., Alford C. A. Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med. 1981 Feb 5;304(6):313–318. doi: 10.1056/NEJM198102053040602. [DOI] [PubMed] [Google Scholar]